Sorafenib is the current standard treatment for patients with metastatic or advanced hepatocellular carcinoma (HCC) that cannot be treated by loco-regional therapy. However, its objective response rate is only 2e3% and the median time-to-progression is around 2.8 months in the Asian population. 1 Other anti-angiogenic agents, such as bevacizumab, have been reported to have similar efficacy.
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The long-term disease-free or cure of advanced HCC by anti-angiogenic therapy alone is extremely rare.
A 24-year-old woman with no history of chronic hepatitis B or C virus infection was diagnosed with HCC in June 2005 by liver tumor biopsy. Computed tomography scans revealed multiple large intra-hepatic tumors extending into the subhepatic area (Fig. 1A) and bilateral lung metastasis (Fig. 1B) . Serum alpha-fetoprotein (AFP) level exceeded 87,500 ng/mL. She was enrolled into a Phase II clinical trial using bevacizumab (7.5 mg/kg, on day 1, triweekly) and capecitabine (800 mg/m 2 , twice daily, days 1e14, triweekly) as the first-line therapy. 3 Partial response was achieved (Fig. 1C) , and all the metastatic lung tumors disappeared (Fig. 1D) . She was treated with the same regimen for a total of 2 years, and the disease was controlled in partial response status. The lowest AFP level was 76,636 ng/mL. years after the surgery, she remained disease-free and her serum AFP level remained normal.
A few case reports have previously described how good outcomes can be achieved with aggressive surgery of metastatic disease. 4, 5 However, these reported cases had either limited or solitary metastasis. Our patient had very extensive disease involvement at diagnosis, so direct surgery was not feasible. To our best knowledge, this is the first reported case describing how an effective systemic therapy converted an initially metastatic and unresectable HCC to resectable status.
A previous case report demonstrated that a complete pathological response was achieved in a locally-advanced HCC patient treated with sorafenib. 6 Our current case demonstration, together with prior case reports, indicates that although advanced HCC is notoriously refractory to most systemic treatment and rapid in progression, multimodality treatment in carefully selected patients might lead to a surprisingly good outcome. 
